
What We’re Reading: US Allows More Formula Imports; Research on SIDS Biomarker; COVID-19 Tests and Boosters
The FDA announces it will streamline the review process to make it easier for foreign manufacturers to ship more formula to the US; researchers in Australia find babies with sudden infant death syndrome (SIDS) have low levels of butyrylcholinesterase in their blood; the federal government approves a third round of COVID-19 test kits and the FDA is expected to authorize booster shots for children aged 5 to 11 years.
FDA Streamlines Review for Baby Formula Imports
The
New Research in SIDS Identifies Potential Biomarker
Researchers in Australia found that children who died of sudden infant death syndrome (SIDS) had low levels of an enzyme named butyrylcholinesterase (BChE), according to the
FDA Approves Booster for Children Aged 5 to 11 Years; Third Round of COVID-19 Tests Available
The FDA expanded its emergency use authorization to
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.